Abstract

Background

The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown.

Methods

We retrospectively analyzed data from breast cancer patients who began treatment with regimens of lapatinib plus capecitabine (LC or LX) or trastuzumab beyond progression (TBP) at eight hospitals between May 2010 and October 2017.

Results

Among 554 patients who had developed resistance to trastuzumab, the median PFS (progression free survival) was 6.77 months in the LX group compared with 5.6 months in the TBP group (hazard ratio 0.804; 95% CI, 0.67 to 0.96; P = 0.019). The central nervous system progression rate during treatment was 5.9% in the LX group and 12.5% in the TBP group (P = 0.018).

Conclusion

The combination of lapatinib and capecitabine showed a prolonged PFS relative to TBP in patients who had progressed on trastuzumab.

Details

Title
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
Author
Yang, Fan; Huang, Xiang; Sun, Chunxiao; Li, Jianbin; Wang, Biyun; Yan, Min; Feng, Jin; Wang, Haibo; Zhang, Jin; Fu, Peifen; Zeng, Tianyu; Wang, Jian; Li, Wei; Li, Yongfei; Yang, Mengzhu; Li, Jun; Wu, Hao; Fu, Ziyi; Yin, Yongmei  VIAFID ORCID Logo  ; Jiang, Zefei
Pages
1-10
Section
Research article
Publication year
2020
Publication date
2020
Publisher
BioMed Central
e-ISSN
14712407
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s12885-020-6639-4
ProQuest document ID
2391414175
Copyright
© 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.